Printer Friendly
The Free Library
19,607,053 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cyanotech Retains Media Relations for Consumer PR Campaign; Focus on BioAstin(R) Natural Astaxanthin.


KAILUA KONA, Hawaii -- Cyanotech Corporation (Nasdaq:CYAN), a world leader in producing high-value nutrition and health products from microalgae, has retained Media Relations, Inc., based in Burnsville, Minnesota, for a broad-based public relations campaign for the company's leading product for human nutrition and health, BioAstin Natural Astaxanthin.

Media Relations will target consumer media, including magazines, newspaper, radio and TV to promote consumer awareness of BioAstin and drive consumers to purchase the product from Cyanotech's customers. These include Now Foods, Health Plus, Twin Laboratories, Jarrow Formulas, Pure Encapsulations, HVL/Douglass Labs, Derma der·ma
n.
See dermis.



derma

the corium, or true skin.
 E and Garden of Life, among others.

"This represents a major initiative by Cyanotech to support our customers' marketing of BioAstin," said Bob Capelli, Vice President of Sales for Cyanotech. "It comes at an opportune time as consumer awareness of natural astaxanthin for such health benefits as fighting inflammation is increasing steadily."

Varied studies have shown the benefit of using BioAstin for varied inflammation-related conditions, including rheumatoid arthritis, carpal tunnel syndrome carpal tunnel syndrome: see repetitive stress injury.
carpal tunnel syndrome (CTS)

Painful condition caused by repetitive stress to the wrist over time.
, joint soreness and sunburn sunburn, inflammation of the skin caused by actinic rays from the sun or artificial sources. Moderate exposure to ultraviolet radiation is followed by a red blush, but severe exposure may result in blisters, pain, and constitutional symptoms. , among others.

Cyanotech is the world's premier supplier of astaxanthin and the largest producer of natural astaxanthin from microalgae.

About Cyanotech

Cyanotech Corporation, a world leader in microalgae technology, produces BioAstin(R) Natural Astaxanthin and Hawaiian Spirulina spirulina

Any cyanobacteria in the genus Spirulina. A traditional food source in parts of Africa and Mexico, spirulina is an exceptionally rich source of vitamins, minerals, and protein, and one of the few nonanimal sources of vitamin B12.
 Pacifica(R) -- all natural, functional nutrients that enhance human health and nutrition, providing significant antioxidant antioxidant, substance that prevents or slows the breakdown of another substance by oxygen. Synthetic and natural antioxidants are used to slow the deterioration of gasoline and rubber, and such antioxidants as vitamin C (ascorbic acid), butylated hydroxytoluene , anti-inflammatory and immune response benefits. NatuRose(R) Natural Astaxanthin is a natural pigment source that also promotes animal health and nutrition, primarily in aquaculture aquaculture, the raising and harvesting of fresh- and saltwater plants and animals. The most economically important form of aquaculture is fish farming, an industry that accounts for an ever increasing share of world fisheries production. . Phycobiliproteins are fluorescent pigments used in medical diagnostic testing and research. Cyanotech produces these products from microalgae grown at its 90-acre facility in Hawaii using patented and proprietary technology. Cyanotech products are distributed to nutritional supplement, nutraceutical, cosmeceutical cos·me·ceu·ti·cal
n.
A cosmetic that has or is purported to have medicinal properties.
, and animal feed makers and marketers in more than 40 countries worldwide. Cyanotech was the first microalgae company in the world to obtain ISO (1) See ISO speed.

(2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI.
 9001:2000 certification. Corporate data and product information are available at www.cyanotech.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995

Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, forecasts of sales in future periods, changes in sales levels to our largest customers, weather patterns, production problems caused by contamination, risks associated with the acceptance of new products, competition, foreign exchange fluctuations, government regulation, and other factors more fully detailed in the Company's recent Form 10-Q and annual form 10-K filings with the Securities and Exchange Commission.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 31, 2006
Words:436
Previous Article:Fitch Rates SASCO's $243MM Series 2006-GEL1.
Next Article:John Hanger of PennFuture, Nationally-Renowned Expert on Energy and Environment, Available for Comment on State of the Union Address.
Topics:



Related Articles
Cyanotech Allies with Unit of Kyowa Hakko for Distribution of BioAstin in Japan; Major Distributor Alliance for Promising Nutraceutical Product.
Cyanotech Hires Public Relations Firm to Promote BioAstin.
Cyanotech Announces Clinical Trial Results for BioAstin; BioAstin Prevents Knee and Joint Soreness and Increases Immune System Response after...
Cyanotech Reports First Quarter Fiscal 2003 Financial Results.
``Microalgae-Based Products Have Many Benefits,'' a Web Radio Series Featuring Interviews With CEOs, by IPOdesktop.com.
Health Benefits of BioAstin and How Cyanotech Expects to Capitalize On Its Unique Properties; A Web Radio Series Featuring Interviews With CEOs, by...
``Interview update on completed financing and positive clinical trials'': A Web Radio Series Featuring Interviews with CEOs, by IPOdesktop.com.
Cyanotech Corporation Retains Guerrant Associates as Its Investor Relations Counsel.
Strategic use of pr yields success for Cargill unit.
Cyanotech Reports Third-Quarter Fiscal 2006 Financial Results; Reports Sales of $2,333,000, Net Loss of $294,000; Webcast is Scheduled for 5:30 pm ET...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles